61results about How to "Good tumor treatment" patented technology

The invention provides a composite gold nanorod carrier having photo-thermal/photodynamic therapy treatment performance and a preparation method thereof. The composite gold nanorod carrier uses a gold nanorod as a core and uses silicon dioxide as a shell layer, a near infrared fluorescent dye for photodynamic therapy is modified on the outer surface of the shell layer. The preparation method comprises the steps that a chloroauric acid solution and a cetyl trimethyl ammonium bromide solution are mixed, a sodium borohydride ice water mixed solution is added to obtain a nano gold seed solution A; a silver nitrate solution and a chloroauric acid solution are added to a binary surface active agent solution, a hydrochloric acid is added after reaction to obtain a solution B, then ascorbic acid and the solution A are added, and a gold nanorod is obtained after reaction; a tetraethoxysilane methanol solution and an aminopropyl trimethoxy silane methanol solution are added to a gold nanorod solution to obtain composite nanoparticles; 1-(3-dimethyl amino propyl)-3-ethyl carbodiimide hydrochloride is added to the near infrared fluorescent dye, then N-hydroxyl succinimide is added to obtain a solution C; the composite nanoparticle solution is mixed with the solution C to obtain a product.

The invention discloses a carrier-free co-assembled tumor targeting anti-cancer nano medicine as well as a preparation method and application thereof. The carrier-free dual anti-cancer nano medicine is prepared from a hydrophobic medicine, namely ursolic acid, together with board-spectrum anti-tumor medicines such as doxorubicin in water through co-assembling, in addition, a fluorescence labeling nucleic acid aptamer, a molecular target, an antibody or polypeptide and the like with tumor targeting functions are adsorbed to the surface of the medicine through mutual electrostatic functions, then the carrier-free co-assembled tumor targeting anti-cancer nano medicine with tumor targeting and tumor microenvironment response is prepared, a synergic anti-tumor function is achieved, diagnosis and treatment integration is achieved, particularly the medicine has outstanding functions in preventing tumor transfer, and more importantly the problems that a conventional nano carrier is complex in system, indefinite in in-vivo metabolism and the like are solved.

The invention discloses a nano-drug for tumor photo-thermal combined iron agent treatment and a preparation method thereof, Fe < 3 + > ions are compounded on carrier protein of metal-protein nano-particles, and meanwhile, pharmaceutically acceptable polyphenol compounds are chelated through the Fe < 3 + > ions. Through experiments, the inventor discovers that different from a traditional method that a Fenton reagent generated in a tumor photothermal treatment process can cause oxidative degradation failure of drug molecules or uncontrollable drug effects, a specific ferroptosis drug is compounded with metal-protein nanoparticles containing polyphenol compounds and used for tumor photothermal treatment; the specific ferroptosis drug and themetal-protein nanoparticles unexpectedly have a synergistic effect and have a better killing effect on tumor cells.

The invention provides a bismuth selenide nanocomposite material and a preparation method and application thereof. The bismuth selenide nanocomposite material comprises polyvinylpyrrolidone, selenocysteine, and bismuth selenide coated by the polyvinylpyrrolidone and the selenocysteine. The bismuth selenide nanocomposite material has a good light-heat conversion function, can achieve effective combination of thermotherapy and radiotherapy to play a synergistic effect, and can overcome respective defects of the two therapy methods to obtain the optimal tumor treatment effect; after completion of the radiotherapy, the selenocysteine is degraded from the surface of the material and can effectively enter a living body to participate in synthesis of selenium protein, so that the body immunity is enhanced, and the side effects caused by the radiotherapy are reduced.

The present invention relates to the field of targeting drug delivery and particularly relates to a tumor targeting drug and a preparation method thereof. The tumor targeting drug comprises a targeting carrier and an anti-tumor drug loaded on the carrier. The targeting carrier comprises hepatitis B virus-like particles a RGD sequence recombinant protein. The tumor targeting drug can be obtained bya genetic engineering method and operation is simple. The tumor targeting drug has good targeting, high bioavailability and small side effects.

The invention relates to a macrophage-mediated drug-loaded hyaluronic acid nanohydrogel and preparation thereof. A drug-loaded hyaluronic acid nanohydrogel is obtained by synthesizing polypyrrole in situ from the interior of a hyaluronic acid nanohydrogel, and loading a drug; and the macrophage-covered drug-loaded nanohydrogel is obtained by performing co-incubation on the drug-loaded hyaluronic acid nanohydrogel and mouse macrophages. The macrophage-mediated drug-loaded nanohydrogel prepared by the method has the advantages of low toxicity, safety, avoidance of phagocytosis of a reticuloendothelial system, and specific targeting in tumor areas when used for delivery of anti-cancer drugs, and has potential application prospects in tumor treatment.

The invention belongs to the field of biological treatment of tumors and relates to an immune cell culture method capable of simultaneously activating CD4 <+>and CD8<+>T cells. The immune cell culture method comprises the steps of placing single nuclear cells which are well separated in a culture solution containing rhIL-12 and IL-4 ligands and an IL-10 ligand, culturing for 8-12h, then adding levamisole, continuously culturing for 8-12h, adding Anti-CD3McAb and rhIL-2, continuously culturing for 2-3 days, and then alternately adding into the culture medium containing the rhIL-2 and the culture medium containing the Anti-CD3McAb and the rhIL-2, wherein the intermediate culture time is 2-3 days. The scheme for preparing a cell factor compound is as follows: collecting cell supernatant liquid within 3-14 days after the beginning of culture, performing low-temperature ultracentrifugation, performing ultrafiltration by an ultrafiltration centrifugal tube, and performing microfiltration by a microprous filtration membrane, wherein filtrate is a natural cell factor mixture. By adopting the culture method provided by the invention, sustained proliferation of cells can be kept for 30 days. NCM contains a variety of cell factors and can stimulate immune cells of a human body to play autoimmune anti-tumor activity.

The invention discloses a CIK cell with high cytotoxic activity and its application in tumor cell immunotherapy. The CIK cell is prepared by the following steps: (1) taking the peripheral blood of a patient, and collecting the peripheral blood mononuclear cell part; The peripheral blood mononuclear cells collected in step (1) were partially centrifuged, and the supernatant was discarded to obtain mononuclear cells; ⁶ /mL cells, add the complete medium containing 500~2000IU/mL gamma interferon and 80~120ng/mL compound (I), and start the induction culture; the complete medium includes RPMI 1640 cell culture medium containing 10% FBS by volume percentage; (4) After 20-28 hours of cell culture in step (3), add 50-1000ng/mL anti-human CD3 monoclonal antibody and 500-2000IU/mL recombinant human IL-2, and continue to induce culture, every 2-3 days The CIK cells were subcultured once, and the induced culture time was 13-21 days to obtain CIK cells. The CIK cells can be used for tumor cell immunotherapy.

The invention relates to the field of camptothecine drugs, in particular to a 10-HCPT (10-hydroxycamptothecine) derivative, a synthesis method and an application thereof. The 10-HCPT derivative is a derivative which is formed by esterifying a hydroxyl radical at site 10 in 10-HCPT and has an ester structure. The molecular polarity of the derivative is greatly reduced, the biological membrane crossing speed is remarkably increased, the speed and the number of drugs entering tumor cells are increased, the utilization of the drugs is increased, the better anti-tumor effect can be realized, and the toxic and side effects are reduced.

The present invention relates to a docetaxel nanometer lipid injection. The invention also relates to a method for preparing the docetaxel nanometer lipid injection. The invention further relates to the application of the docetaxel nanometer lipid injection for preparing medicament for treating a tumor. The nanometer preparation of the invention is capable of prolonging the medicament action time, conveying the medicament with a target, reducing the administration dose under the precondition of ensuring the medicament action, alleviating or avoiding medicament toxin and side effects, improving the medicament action stability, and being benefited for the medicament storage, thus it is capable of implementing the development of the medicament which has advantages in the aspects of a high yield, automatization, large scale, low cost, convenient carry and storage, small dose and low side-effect.

The invention discloses CIK cells with high cytotoxic activity for immune treatment of tumor cells. The CIK cells are prepared through the following steps that firstly, peripheral blood of a patient is sampled, and the peripheral blood mononuclear cell part is collected; secondly, the peripheral blood mononuclear cell part collected in the first step is centrifuged, supernate is discarded, and mononuclear cells are obtained; thirdly, the mononuclear cells are taken according to 1*106/mL, and a complete medium including 500-2,000 IU/mL of gamma interferon and 80-120 ng/mL of a compound is added, and induction culturing is started, wherein the complete medium includes RPMI 1640 cell culture fluid with 10% of FBS by the volume percent; fourthly, after the cells in the third step are cultured for 20-28 hours, 50-1,000 ng/mL anti-human CD3 monoclonal antibodies and 500-2,000 IU/mL of recombination human IL-2 are added, induction culturing is continued, subculture is conducted once every other two to three days, the induction culturing time is 13 to 21 days, and the CIK cells are obtained. The CIK cells can be used for immune treatment of the tumor cells.

The invention provides a pulsed magnet field generator based on coil spherical focusing and IGBT single transistor parallel connection. The pulsed magnet field generator comprises a power supply system, a pulse current forming system, five coil spherical optimization focusing devices, a signal transformation system and a synchronized trigger module, and the switching power supply of the power supply system carry out voltage reduction on an alternating current power supply to form direct currents, is connected with the pulse current forming system, the signal transformation system and the synchronized trigger module and supplies power. The output ends of pulse generating modules M1-M5are connected with current carrying coils C1-C5 in the five coil spherical optimization focusing devices respectively. The electrical-optical converter J2 of the signal transformation system is respectively connected with the control ends of the pulse generating modules M1-M5. The output end of the synchronized trigger module is respectively connected with the electrical-optical converter J1 and the electrical-optical converter J2 of the signal transformation system. The pulsed magnet field generator is high in integration level, longer in service life and higher in work efficiency, the circuit size is greatly reduced, and the loss of the whole circuit is lowered.

The invention provides a recombinant human serum albumin-collagen binding domain fusion protein of a tumor specific targeting matrix and application, and relates to the technical field of biological medicines. According to the invention, gene fusion is formed by utilizing HSA and CBD in different molecular structure forms, expression can be obtained in a constructed recombinant engineering host, and the recombinant fusion protein meeting medicinal requirements is obtained through large-scale fermentation preparation. The recombinant fusion protein has solid tumor specific targeting, can be used as a broad-spectrum matrix carrier starting material, and can be coupled with any tumor treatment drugs, small molecular compounds or cytotoxic proteins to form an innovative drug compound. The recombinant fusion protein drug compound also has long-acting property, can prolong the half-life period of a coupling drug in vivo, and has a clinical curative effect obviously superior to that of a monomeric drug in tumor resistance. The invention also provides an application of the drug compound in preparation of drugs for solid tumor specific targeted therapy and preparation of corresponding drugs.

The invention relates to a bionic nano-carrier for reducing excessive calcium ions in tumors and a preparation method and application thereof. The preparation method comprises the steps that a mixed solution of triethylamine and monobrominated polyethylene glycol is added into a gold nanoparticle solution modified with a calcium ion trapping agent, a reaction is conducted for 1-3 days under stirring, dialysis is conducted, and a bionic nanoparticle solution with the calcium ion trapping agent protected by polyethylene glycol is obtained; a mixed solution of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, N-hydroxysuccinimide and a tumor targeting agent is added into the bionic nanoparticle solution with the calcium ion trapping agent protected by polyethylene glycol, a reaction is conducted for 1-3 days under stirring, dialysis is conducted, and the calcium-ion-trapped bionic nanoparticle solution with a tumor targeting function is obtained. The prepared bionic nano particles are good in biocompatibility, safe, non-toxic, excellent in stability and suitable for the medical field; and the choices of the calcium ion trapping agent and the tumor targeting agent used herein are wide-ranging, and the modification method is simple.

The invention provides a cervical cancer therapeutic vaccine based on recombinant attenuated Listeria monocytogenes and a preparation method of the cervical cancer therapeutic vaccine, and relates tothe field of genetic engineering. The attenuated Listeria monocytogenes Lemo-C07 are taken as a background, and a virulence factor LLO protein of the strain carries two key mutant amino acid sites, sothat the virulence of the strain is greatly reduced, but part of the proliferation ability in the cells is still retained. According to the vaccine, on the basis of the attenuated Listeria monocytogenes, a molecular biological technique is utilized to integrate a full-length gene of a specific antigen E7 of the cervical cancer to the downstream part of an LLO gene of the Listeria monocytogenes, thereby constructing and obtaining the recombinant attenuated Listeria monocytogenes containing the tumor specific antigen E7. The vaccine has the capabilities of presenting the specific antigen and activating the anti-tumor cellular immunity of the body, and has the remarkable tumor treatment effect.

The invention discloses an EGFR (epidermal growth factor receptor) inhibitor and medical application thereof. The compound is a compound as shown in a formula I, pharmaceutically acceptable salt or prodrug. The compound can be applied to preparation of medicines for treating and/or preventing cancer.

The invention discloses novel iridium complexes as well as a preparation method and application thereof. The iridium complexes are formed by combining electron-deficient naphthoquinoline or pyrazine serving as an N^N ligand with a large conjugated C^N ligand with an electron donating property. The iridium complexes with rich excited states can be subjected to energy transfer with oxygen under the illumination condition to generate rich singlet oxygen, and under the hypoxic condition, the iridium complexes can generate active oxygen species such as hydroxyl free radicals due to relatively strong electron transfer, so that the iridium complexes have a good photodynamic effect; besides, the N^N ligand with electron-deficient property and the C^N ligand with electron-donating property respectively regulate HOMO and LUMO energy levels, so that the iridium complexes emit red light and have a better application prospect in the field of biological imaging materials.

The invention discloses a quinazoline derivative serving as an EGFR inhibitor and application of the derivative. The quinazoline derivative is a compound shown in formula I and is pharmaceutically acceptable salts or prodrugs. The compound can be used for being prepared into drugs for treating and/or preventing cancers, wherein the formula I is shown in the description.

The invention discloses a CDK4-FLT3 inhibitor and an application of the CDK4-FLT3 inhibitor. The compound is a compound shown as a formula I, and pharmaceutically acceptable salt, hydrate, solvate, metabolite, stereoisomer, tautomer or prodrug thereof. The compound can be used for preparing medicines for treating and/or preventing cancers.